123 related articles for article (PubMed ID: 6678794)
1. Hypothesis: macrophages as effector cells for human tumor destruction mediated by monoclonal antibody.
Steplewski Z; Herlyn D; Maul G; Koprowski H
Hybridoma; 1983; 2(1):1-5. PubMed ID: 6678794
[No Abstract] [Full Text] [Related]
2. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.
Steplewski Z; Sun LK; Shearman CW; Ghrayeb J; Daddona P; Koprowski H
Proc Natl Acad Sci U S A; 1988 Jul; 85(13):4852-6. PubMed ID: 3387441
[TBL] [Abstract][Full Text] [Related]
3. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.
Herlyn D; Koprowski H
Proc Natl Acad Sci U S A; 1982 Aug; 79(15):4761-5. PubMed ID: 6289317
[TBL] [Abstract][Full Text] [Related]
4. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis.
Adams DO; Hall T; Steplewski Z; Koprowski H
Proc Natl Acad Sci U S A; 1984 Jun; 81(11):3506-10. PubMed ID: 6587365
[TBL] [Abstract][Full Text] [Related]
5. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
8. Destructive interactions between murine macrophages, tumor cells, and antibodies of the IgG2a isotype.
Johnson WJ; Steplewski Z; Koprowski H; Adams DO
Adv Exp Med Biol; 1985; 184():75-80. PubMed ID: 2931004
[No Abstract] [Full Text] [Related]
9. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.
Hellström I; Beaumier PL; Hellström KE
Proc Natl Acad Sci U S A; 1986 Sep; 83(18):7059-63. PubMed ID: 3462743
[TBL] [Abstract][Full Text] [Related]
10. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.
Schulz G; Bumol TF; Reisfeld RA
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5407-11. PubMed ID: 6577434
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
13. Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation.
Johnson WJ; Steplewski Z; Matthews TJ; Hamilton TA; Koprowski H; Adams DO
J Immunol; 1986 Jun; 136(12):4704-13. PubMed ID: 3711663
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human tumor growth by IgG2A monoclonal antibodies correlates with antibody density on tumor cells.
Herlyn D; Powe J; Ross AH; Herlyn M; Koprowski H
J Immunol; 1985 Feb; 134(2):1300-4. PubMed ID: 3965572
[TBL] [Abstract][Full Text] [Related]
15. In vivo destruction of canine lymphoma mediated by murine monoclonal antibodies.
Steplewski Z; Rosales C; Jeglum KA; McDonald-Smith J
In Vivo; 1990; 4(4):231-4. PubMed ID: 2103365
[TBL] [Abstract][Full Text] [Related]
16. Targeted cellular immunotherapy with bifunctional antibodies.
Nelson H
Cancer Cells; 1991 May; 3(5):163-72. PubMed ID: 1832553
[TBL] [Abstract][Full Text] [Related]
17. Production of anti-tumor human monoclonal antibodies using different approaches.
Liu H; Xu ZL; Wang Y; Yang L; Feng O; Li Y; Wang YM; Zhang GG
Hum Antibodies Hybridomas; 1993 Jan; 4(1):2-8. PubMed ID: 8381684
[TBL] [Abstract][Full Text] [Related]
18. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
19. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells.
Steplewski Z; Lubeck MD; Koprowski H
Science; 1983 Aug; 221(4613):865-7. PubMed ID: 6879183
[TBL] [Abstract][Full Text] [Related]
20. Antibody-mediated killing of human tumor cells by attached effector cells.
Hellström I; Garrigues U; Lavie E; Hellström KE
Cancer Res; 1988 Feb; 48(3):624-7. PubMed ID: 3335025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
